On or around 02/12/2019 (Notice of voluntarily dismissal)
Filing Date: January 24, 2019
According to the Complaint, Loxo is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.
This action stems from a proposed transaction announced on January 7, 2019 (the “Proposed Transaction”), pursuant to which Loxo Oncology, Inc. (“Loxo” or the “Company”) will be acquired by Eli Lilly and Company.
On January 5, 2019, Loxo’s Board of Directors caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”) with Eli Lilly. On January 17, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction.
The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.
This case was voluntarily dismissed on February 12, 2019.
Company & Securities Information
Defendant: Loxo Oncology, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: LOXO
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Colleen Witmer, et al. v. Loxo Oncology, Inc., et al.